Archives

October 2008
Hurricanes Taking Toll on Petrochemical Industry
Following Hurricane Gustav, many chemical plants in Louisiana remained without power for an extended period. Three Caustic soda producers temporarily declared force majeure (FM), contributing to heightened tightness in that market. Two Ethylene glycol manufacturers also declared FM in the wake of the storm, as did a Melamine producer. Fortunately, power was restored within a few days, and most manufacturers were able to return to normal operations within a week or so.

Before companies in Louisiana could fully recover from Gustav, firms located in the Houston area had to prepare for the onslaught of massive Hurricane Ike. Up to 100 petrochemical facilities in Texas were affected by the storm, but none seriously. As with Gustav, the major issue has been power restoration, and it may takes several weeks for many plants to return to business. A great number of facilities were still working to restart operations more than two weeks after the storm. Chemical shipments were down dramatically, reflecting the lost production and damaged shipping infrastructure.

Two drilling rigs were torn from their moorings. Practically all crude oil and about 94 percent of natural gas production in the Gulf remained shut in several days after Ike passed through the area. The port of Houston was clogged with debris and over a hundred ships lingered, waiting to unload. The Coast Guard was working to clear ship lanes, but was also struggling without power. It will take weeks to make the Houston Ship Channel fully navigational.

There is concern about Ike's possible impact on the already struggling U.S. economy. In addition to potential fuel shortages and higher prices, many industries that have remained strong during the downturn could be hurt by the extended shutdowns of chemical plants in the Gulf region.
 

 

CIS Adds New Enriched Company Feature to DWCP

Chemical Information Services continues to deliver essential, high quality information to the chemical and pharmaceutical industries by launching the latest addition to its flagship product, the Directory of World Chemical Producers (DWCP). The DWCP Enriched Company Listing program will enable participating companies to enhance their current listing with a multitude of documents such as ISO Certifications, REACH Authorization, White Papers, and product price lists, just to name a few. This expanded listing offers producers additional opportunities to display their valuable company information to key decision makers and stand out at the point of purchase.

 



 
Court Hands Down Decision in Hexion/Huntsman Quarrel

Huntsman prevailed in the recent court battle with Hexion when the Delaware Court of Chancery determined that Hexion could not break its $10.6 billion merger deal with Huntsman. The court also found that Hexion breached a number of obligations and possibly exposed itself to liabilities for damages excedding the $325 million break-up fee it has disputed.. Hexion must take all actions necessary to bring the deal to a close. In a separate ruling by a Texas district court, Huntsman also obtained a temporary restraining order preventing Hexion's lenders from blocking financing for the deal. Huntsman is also seeking $3 billion in damages from Hexion's owner Apollo Management in another Texas lawsuit.

 



 
Evonik Unloads North American Cyanides Business

Oaktree Capital Management agreed to acquire the U.S. and Canadian cyanide business of Evonik Industries for an undisclosed amount. The business is part of Evonik's CyPlus Group that is dedicated to the gold-mining industry. The deal includes a 50 percent share in Cyanco, a joint venture with Nevada Chemicals, and the involvement of subsidiaries CyPlusCanada and CyPlus Corp. Activities of CyPlus in Europe will remain part of Evonik's Hydrogen cyanide network.

 



 
Leading Chinese Firm to Make Big Investment

Ningxia Refining and Chemicals Company, a subsidiary of leading Chinese company PetroChina, will invest $1.19 billion (CNY 8.2 billion) in a refinery project in Ningxia province. The complex will include a 100,000 tonne/year Polypropylene (PP) unit and other facilities not yet detailed. Construction is underway, and the company expects the plants to be operational by the end of 2010.

 



 
Ranbaxy Drugs Banned from Importation by FDA

As a result of a recent investigation into manufacturing practices at Ranbaxy Laboratories, the FDA announced that it is taking "preventive action" and banning the importation of 28 generic prescription drugs from the Indian company. The agency identified manufacturing deficiencies at two Ranbaxy production facilities, but stated there was "no evidence of harm to consumers" resulting from the problems. The FDA sent two warning letters to the company about failure to comply with current good manufacturing requirements, but despite efforts to work with the company, Ranbaxy failed to correct the deficiencies. Specific problems related to "inadequate sterile processing operations" and inadequate recordkeeping. Separately, the Justice Department is investing allegations that Ranbaxy submitted falsified data to the FDA to get the approval to sell AIDS drugs to U.S. government funded organizations.

Ranbaxy has hired Giuliani Partners to "advise and review" the compliance situation and said it would cooperate with the FDA.
 

 



 
Reorganization in the Works for Akzo Nobel
Akzo Nobel is implementing a new cost reduction program to achieve annual savings of $100 million. The program includes elimination of 3,500 positions --about 5.8 percent of its workforce -- by 2011. The company will also defer a share buyback program and a $2.6 billion (Euro 1.8 billion) dept repayment plan.

Akzo also established operational goals that include managing the margins of its specialty chemicals business, focusing on organic growth in its performance coatings segment and re-branding its decorative paints operations.
 

 



 
Repsol Expanding Portugal Operations
Repsol will invest $1.4 billion (Euro 1 billion) in its Sines, Portugal, facility to expand its cracker capacity and polyolefin units, which are anticipated to be online in 2011. This announcement increases the expenditure initially reported and delays the start-up by one year.

 



 
SAFC Expands Potent Capacity
SAFC will invest $30 million (Euro 20.7 million) to increase capacity for the production of highly potent APIs in Wisconsin. The new facility, located in Verona, will be built on 15 recently acquired acres and will include a 45,000ft² (4,200m²) building that houses two 4,000-litre reactors, giving the company the ability to produce large quantities of highly potent compounds. The plant should be operational by the end of 2009. SAFC recently completed a $15 million expansion of capacity for highly potent APIs at its Madison, Wisc. site.

 



 

 
Chemical M&A Continues with Big and Small Deals
While big deals such as the acquisition of Rohm and Haas by Dow Chemical and the takeover of Hercules by Ashland, smaller and medium-sized transactions will likely be as important. In the first half of 2008, $36 billion worth of M&A deals took place, while in all of 2007 deals totaled $55 billion. The number of deals above $25 million was just 34 in 2006, however. There were 81 such high-value deals in all of 2007, reflecting the deepening credit crisis. Mergers and acquisitions will continue, though, according to analysts, because the key drivers are still in place. In many cases, the economy has led companies to identify businesses ripe for divestiture. Some also expect that the Dow/Rohm and Haas deal to serve as a catalyst for other companies considering a move of their own. More and more deals will take place in Asia, the Middle East and Latin America as those markets look to consolidate and international companies look to gain a foothold.

 



 
Feedstock Availability Curtails Growth in Latin America
Limited raw material supply is making it difficult for the petrochemical industry in Latin America to attract the necessary investment required for expansion. Countries will likely have to rely on imports to meet growing demand. Without additional investment in the industry, companies will not be able to gain access to the natural resources in the region.

 



 
Thai Chemical Industry Impacted by Political Conflicts
The final ouster of the Thai prime minister following weeks of protest and unrest in the country does not provide much reassurance to members of the chemical industry. The political turmoil in the country has resulted in reduced foreign investment, severely limiting access to capital. Domestic consumer demand has also declined due to the uncertainty in the country. Major government projects, such as a mass-transit railway, are also likely to be delayed. And there is no indication that the person who assumes power will be able to provide stability.

 



 
Top 100 Companies Enjoyed a Strong 2007
BASF is once again first on the annual lists of top chemical companies according to two leading chemical industry magazines. Chemical firms are ranked by annual sales in 2007. Dow Chemical, the chemical operations of ExxonMobil and Shell, LyondellBasell, INEOS, SABIC, Sinopec, Mitsubishi Chemical and DuPont round out the top ten on the ICIS Chemical Business list, while Chemical Week's top ten includes Dow Chemical, INEOS, ExxonMobil and Shell, Sinopec, DuPont, SABIC, Total and Mitsubishi Chemical. Both lists reflect the global nature of the industry. Demand growth in emerging countries in Asia, Central and Eastern Europe and Latin America led to strong growth, despite the slowdown in North America. Both volume and price increases were achieved, with fertilizer and agchem companies making the greatest gains. Acquisitions helped others advance on the list. Overall profits grew by more than 12 percent, while the operating margin for this industry increased by 6 percent.

 



 
Turbulence in Financial Markets Affects Chemical Industry
Limited availability of credit and higher financing costs could negatively impact chemical industry projects. The higher cost for construction materials and equipment are already driving up overall project costs. Some projects in the Middle East are now uncertain, but those in Europe and the United States are most strongly affected. The $700 billion bailout passed by the U.S. Congress should help chemical companies maintain revenue streams and continue to borrow. It may also lead to increased merger and acquisitions activity. However, many are concerned that the reduced availability of credit will lead to a drop in demand for downstream products.

 



 

 
BASF on Acquisition Trail Again: Snapping Up Ciba
BASF has made a $5.5 billion (Euro 3.9 billion) offer for Ciba Specialty Chemicals, and Ciba's board has recommended that shareholders accept it. The acquisition will strengthen BASF's position in specialty materials with the addition of Ciba's operations in plastics additives, coating effects and water & paper treatment chemicals, which BASF will merge with its performance products segment. Ciba gains access to BASF's global research, production and marketing capabilities and its integrated position in raw materials and intermediates. BASF will establish a global operating division at Ciba's headquarters in Basel, Switzerland, and retain its R&D site there. BASF expects the deal to be finalized some time the first quarter of 2009.

 



 
Paraffin Wax Cartel Members Fined
The European Commission (EC) fined nine Paraffin wax producers $952 million (Euro 676 million) for operating a pricing cartel between 1992 and 1995. Companies in the cartel include ENI, ExxonMobil, Hansen & Rosenthal, Tudapetrol, MOL, Repsol, Sasol, RWE and Total. Although a member of the cartel, Shell was not fined because it cooperated with the EC. Sasol was fined the largest amount as the leader of the group, and ENI's fine was higher than the others, because they have been accused of participating in similar cartels in the past.

 



 

 
Consolidation Expected in Chinese Pharma Sector
According to Frost & Sullivan, the $22 billion Chinese pharma market (2007) will grow to be one of the top five in the world by 2010. Between now and then, they predict increased consolidation of the 30,000 plus companies as well as growing investments in R&D. The government aims ultimately to have 20 to 30 large players that produce high quality products. Currently, generics for domestic consumption and advanced pharmaceutical ingredients (APIs) for export account for most Chinese pharma sales. The recent heparin tragedy and other incidents have highlighted, however, quality issues in the country's pharma sectors. To remain successful, companies will need to improve quality and service and perform at international standard levels -- rather than focusing solely on offering a lower cost.

 



 
FDA Expands Workforce by 1,300, Upgrades IT
The FDA has expanded its personnel by about 10 percent, adding about 1,200 new employees. The Center for Drug Evaluation and Research (CDER) will get 663 of the new employees. About 75 percent have started working, an additional 11 percent will start by the end of September, and another 11 percent are undergoing background checks. Of those already working, 85 percent are professionals, such as chemists, biologists, pharmacologists, statisticians, medical officers, microbiologists and field inspectors.

Overseas offices will be established in China, India, Europe, Latin America and the Middle East, and some country directors, technical experts and inspectors have been hired already. These jobs are going to existing FDA personnel to ensure that people with experience fill the positions.

The agency also announced that it will invest $2.5 billion over the next 10 years to upgrade its IT systems. Ten different contractors will work to implement two new data management systems for data tracking.
 

 



 
Pharma Hopes Rest on Biologics Buys
Facing numerous patent expirations, growing generics competition, rising discovery and development costs and a lengthening approval process, pharma companies are turning to life science firms with biologics technology to increase their pipeline offerings. Whether through mergers and acquisitions or licensing deals, big pharma is betting on collaborations to identify potential new drugs that will positively impact the bottom line. Nearly one-third of the pipelines of the top 10 pharma companies are in-licensed products, according to PAREXEL. Even leading biotech companies are in-licensing technology to expand their pipelines.

 



 
Pharma Turns to Academic Investments
Major pharma companies like AstraZeneca (AZ), Pfizer and GlaxoSmithKline (GSK) are investing in partnerships with academic institutions to expand their research capabilities. AZ is collaborating with Columbia University, GSK is linking up with Harvard, and Pfizer is working with four different institutions. In these new relationships, industry and university scientists are working toward the acceleration of the drug-discovery process after patent and publication rights are established.

The increased activity between big pharma and universities has attracted the attention of Congress. Senator Charles Grassley (R-Iowa) wants the National Institutes of Health (NIH) to revoke grants awarded to universities that do not disclose financial ties to drug manufacturers. The agency spent greater than $23 billion on educational research projects. Institutions like Harvard and Stanford Universities are in response considering how to handle funding from pharma companies.
 

 



 
Sanofi-Aventis Makes Move in Eastern Europe

Sanofi-Aventis announced that it will acquire Czech generic drug producer Zentiva for $2.6 billion. The deal is 9.5 percent higher than Sanofi's original offer. With the move, the company gains a foothold in the rapidly growing emerging markets in Eastern and Central Europe. Current Zentiva CEO Jiri Michal will remain as head of the business. The deal still requires the approval of shareholders and relevant authorities.

 



 
Shionogi Acquires Sciele Pharma

Japanese firm Shionogi & Co. has agreed to acquire U.S.-based Sciele Pharma for $1.4 billion. The purchase provides Shionogi with an extensive sales force in the United States that will help introduce its growing pipeline to this key market. Three drugs are expected to receive FDA approvals in 2012.

 



 

 
Green Light for Growth in Ag Chem Sector
Both sales and profits have been up for leading agrochemical firms in 2007 and the first half of 2008, and more growth is expected. Companies are investing in R&D to develop new technologies that improve crop productivity, from protection products to hybrid seeds and biotech-based plant varieties. Much of the growth has been driven by higher prices for both agricultural commodities and chemicals, which are beginning to decline. However, the increasing biofuels sector, larger planted areas and other factors will continue to support further growth for the sector.

 



 

 
Big Investments in Refining for Chinese Company
China National Offshore Oil Corp. (CNOOC) announced plans to invest about $6.6 billion to expand its refining and Ethylene production capacity. Refining capacity will grow from 12 million to 22 million tonnes/year. Construction is slated to begin in 2009, with the facility becoming operational in 2011.

 



 
Ethanol Production in Brazil to Get Investment Boost
Ethanol producers in Brazil recently announced investments totaling about $4 billion in its sugar cane-to-Ethanol operations. Bunge and Itochu will spend $800 million on two plants, while ETH Bioenergia will spend $3.3 billion on 10 new facilities by 2013.

 



 
Petchem Prices Declining in Asia
The falling price of crude in the end of August and first half of September had a dramatic impact on prices of commodity chemicals in Asia, which have declined considerably. Even the recent spike in crude oil values is not likely to have an impact. Many expect downstream demand, which is already weak, to slow down further, as buyers wait to see if prices will go still lower. Styrenic compounds have seen spot prices drop as much as 8 percent, while Benzene and Toluene fell to a seven-month low. Declining raw materials costs are expected to lead to some of the lowest prices seen in Asia for solvents in some time. Polyolefin prices experienced the biggest drop in prices in the last 10 years.

Traditionally, downstream consumption rises in the third quarter, but restrictions on the production and transport of chemicals surrounding the Olympic Games in China dramatically affected the market. Prices could drop even further with the upcoming Chinese National Day holiday in early October. The subprime crisis, growing global economic slowdown and recent crises in Western financial markets, combined with increased capacity in the Middle East, will further exacerbate the market conditions in Asia. As a result, economists are predicting a major downturn in the region.
 

 



 

 
Symrise on the Move in North America

Flavor and fragrance manufacturer Symrise is expanding operations in the United States. Recently, the company recently acquired Intercontinental Fragrances and Manheimer Fragrances and announced plans for a new R&D center. Both Intercontinental and Manheimer make fragrances for the candle market. Manheimer also provides products to the air freshener market. The acquisitions will enhance Symrise's position in air care fragrances in North America.

 



 

 
BASF Sells North American Coil Coatings Business to PPG
PPG Industries will acquire the North American coil and extrusion coatings business of BASF for an undisclosed amount. Production will continue from BASF's plants for approximately one year, after which time manufacturing operations will be moved to PPG facilities. PPG plans to retain the technical and sales capabilities of the business to become better positioned to provide innovative technologies, high-quality products and superior customer service, according to PPG Senior Vice President William Wulfsohn.

Separately, PPG announced that it completed the sale of its automotive glass business to private equity firm Kohlberg & Co. for $330 million. Kohlberg renamed the business Pittsburgh Glass Works. PPG retained a 40 percent stake. PPG will also close several plants in Canada, Europe and the U.S. as part of a reorganization plan aimed at providing $100 million in annual pre-tax savings by the end of 2009.
 

 



 

 
Polymer Makers Traveling Rocky Road
Maintaining margins for polymer makes has become a real challenge. Demand is weak, feedstock costs are up and significant additional capacity is coming on-stream. Analysts predict that only companies with an established feedstock position and modern, highly efficient production facilities will be able to remain competitive. Polyolefin buyers are holding off, partially in anticipation of lower prices for Polyethylene and Polypropylene, and partially due to uncertainty in downstream markets. Demand is predicted to slow further as a result of the recent financial crisis in the United States, which has affected global markets as well. In China, polymer sales growth may be flat or possibly negative in 2008.

 



 
Slow Polymer Market in India -- Europeans Face Higher-than-Expected Ethylene Prices
Indian polymer manufacturers cut prices as much as 7 percent to encourage buying interest in a slow domestic market. Little reaction has been observed for Polyethylene (PE), Polypropylene (PP) or Polyvinyl chloride (PVC). Buyers are holding out for further price cuts. In Europe, Polyethylene producers are finding that Ethylene prices are not dropping nearly as much as anticipated based on the decline in crude oil prices. An initial fourth quarter contract price was set about 40 percent higher than expected. Demand for PE in the region remains weak.

 



 

 
Indian Resistance to Tata Factory Bodes Ill for Manufacturing in the Country

Tata Motors is facing large numbers of protestors who do not want to see the company build a plant for its Nano car in Singur, West Bengal. Protesters claim that hundreds of acres were forcibly taken from landowners on behalf of the company, and that the farmers were compensated inadequately. Protests on a smaller scale are occurring across the country, with public opposition to new manufacturing facilities on the rise. Planned petrochemical hubs are being delayed or dropped as a result of this opposition, which is focuses largely on displaced people, but targets environmental concerns as well.

 



 
Pre-registrations for Reach Surpass 350,000 While Agency Faces Shortfall

As of Sept. 15, 2008, 352,641 pre-registration applications for the European Union's Registration, Evaluation and Authorization of Chemicals (Reach) program were received by the European Chemicals Agency (ECHA) -- a number far greater than the 200,000 the agency expected. The ECHA fears that companies are pre-registering substances that they will not pursue to full registration, and that revenues will be thereby lower than expected. Two companies, for example, filed pre-registrations for the entire Reach inventory; European distributor Azelis is one of the two. The company, which sells more than 40,000 products, took this action to prevent the possibility of unknowingly selling unregistered substances.

The ECHA announced that it was changing the rules for Reach pre-registration, restricting the amount of substances that can be pre-registered electronically to 10,000. Approval from the ECHA must be obtained if a company wishes to pre-register a greater number. Some complained that the agency previously encouraged companies to err on the side of caution and pre-register all substances they weren't sure about, but that the agency is now saying that only products that will ultimately be fully registered should be submitted. The pre-registration time period closes at the end of November 2008.
 

 



 

 
Clariant Names New Head
Hariolf Kottmann has been named as the new CEO of Clariant, effective Oct. 1, 2008. According to the company, Kottmann replaces Jan Secher, who is leaving to pursue new activities. Kottmann is leaving his position as board member of SCL Carbon. Previously, he also served as a board member with Celanese and the former Hoechst AG. Some analysts were surprised that Clariant made the personnel change in the midst of a major restructuring and view it as a sign of instability. Others see Secher's departure as an indication that the restructuring program is not working.

 



 
DuPont to Have New Leader in 2009

When current CEO Charles Holliday retires as of Jan. 1, 2009, Ellen Kullman will take his place as CEO. Kullman will also assume the responsibilities of president and director beginning Oct. 1, 2008. Holliday will remain as chairman and a member of the board, with Kullman expected to take up these positions eventually.

Kullman most recently served as an executive vice president with DuPont and was responsible for four business segments as well as the company's marketing, sales and environmental sustainability functions. Analysts do not expect Kullman to make any major strategic changes, but they do anticipate that she will address the company's current cost structure and expand DuPont's seed and crop protection portfolio.
 

 



 
New CEO for Neste Oil

Deputy CEO Jarmo Honkamaa is serving as president and CEO of Neste Oil until Oct. 1, 2008, when Matti Lievonen will take on responsibility for the positions. The jobs were vacated by Risto Rinne, who retired due to health reasons. Lievonen served previously as the president of UPM-Kymmene's fine and specialty papers division.

 



 
New Head for PKN Orlen
Jacek Krawiec, deputy CEO, has been appointed as CEO of PKN Orlen, replacing Wojciech Heydel, who recently announced his resignation. Analysts were expecting the change in leadership; Heydel did not agree with many of the strategies preferred by the Treasury Ministry, which is the largest shareholder. These strategies include exiting the chemical and fertilizer businesses and finding additional sources for crude oil other than Russia.

 



 
Sasol Must Replace Chairman
Pieter Cox, Chairman and Director of Sasol, is resigning from the company effective Nov. 28, 2008. Current board member Hixonia Nyasulu has been appointed as his replacement. Professor Juergen Schrempp has been named as lead independent director.

 



 

 
Famous Quotes of the Month

"The best way to have a good idea is to have lots of ideas." (Linus Pauling)

"Imagination is more important than knowledge." (Albert Einstein)

"In any moment of decision the best thing you can do is the right thing, the next best thing is the wrong thing, and the worst thing you can do is nothing." (Theodore Roosevelt)
 

 



 

 
Why do pigs have curly tails?
It's probably just a quirk of nature and a part of a pig's genetic makeup.

One thing that zoology experts will mention and that people who raise pigs will tell you is this: When the tail goes straight, it's usually a sign of the pig's ill health. The straighter the tail, the more likely it will have parasites. Thanks to this adage, whenever a pig's curly tail becomes straighter, the vet gets a phone call!
 

 



 

 
In This Issue

 
Featured Article
 
Companies
 
Business/Finance
 
Fine & Specialty Chemicals
 
Pharma
 
Agrochemicals
 
Commodity Chemicals
 
Flavor & Fragrance
 
Paints & Coatings
 
Plastics
 
General
 
Personnel
 
Famous Quotes
 
Imponderables
 

 






 

 

Corporate HQ:
9101 LBJ Frwy., Suite 310
Dallas, TX 75243 USA
Tel: (214) 349-6200
Fax: (214) 349-6286

Unsubscribe or update your email address.
Email Marketing
9101 LBJ Frwy., Suite 310 | Dallas, TX 75243